Last reviewed · How we verify

Hereditary C1 esterase inhibitor deficiency - deficient factor — Treatment Landscape & Competitive Intelligence

Hereditary C1 esterase inhibitor deficiency - deficient factor (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Hereditary C1 esterase inhibitor deficiency - deficient factor, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Ruconest CONESTAT ALFA Pharming Group N.V. 2010-01-01
Ruconest Ruconest Bernstein Clinical Research Center

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Bernstein Clinical Research Center · 1 drug in Hereditary C1 esterase inhibitor deficiency - deficient factor
  2. Pharming Group N.V. · 1 drug in Hereditary C1 esterase inhibitor deficiency - deficient factor

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Hereditary C1 esterase inhibitor deficiency - deficient factor:

Cite this brief

Drug Landscape (2026). Hereditary C1 esterase inhibitor deficiency - deficient factor — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/hereditary-c1-esterase-inhibitor-deficiency-deficient-factor. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing